Uticaj mio-inozitola na glikoregulaciju i lipidni profil

Veroslava Stanković; Dragana Jović; Simonida Mitić; Sava Mitić; Andrijana Zuber

doi:10.5937/erhs3-56419

Veroslava Stanković Akademija strukovnih studija Beograd, Odsek Visoka zdravstvena škola, Srbija https://orcid.org/0000-0003-3241-6230
Dragana Jović Institut za javno zdravlje Srbije"Dr Milan Jovanović batut", Beograd, Srbija https://orcid.org/0000-0002-2657-9909
Simonida Mitić New Med, Beograd, Srbija https://orcid.org/0009-0008-1378-8606
Sava Mitić New Med, Beograd, Srbija https://orcid.org/0009-0004-1055-0142
Andrijana Zuber Centar za ishranu "Dr Andrijana Zuber", Beograd, Srbija https://orcid.org/0009-0009-2288-6176

DOI: https://doi.org/10.5937/erhs3-56419

Ključne reči: mio-inozitol, insulinska osetljivost, lipidni profil, glikoregulacija

Sažetak

Mio-inozitol je privukao pažnju zbog svog potencijalnog terapeutskog dejstva u lečenju metaboličkih poremećaja, posebno dijabetes melitusa i poremećaja lipidnog statusa. U ovom radu istražena je uloga mio-inozitola u regulaciji metabolizma glukoze, insulinske osetljivosti i lipidnog profila, sa posebnim fokusom na njegov uticaj na dijabetes tipa 2 i povezane poremećaje lipida. Mio-inozitol igra ključnu ulogu u signalizaciji insulina, regulišući delovanje insulina u ciljnim tkivima, poboljšavajući unos glukoze i smanjujući insulinsku rezistenciju. Kliničke studije pokazuju da suplementacija mio-inozitolom može dovesti do značajnih poboljšanja u kontroli glikemije, uključujući smanjenje nivoa jutarnje glikemije i HbA1c i, takođe, utiče na lipidni profil smanjujući ukupan holesterol, LDL i trigliceride, te povećavajući vrednost HDL. Takođe, mio-inozitol pokazuje potencijal u rešavanju komplikacija povezanih sa dijabetesom, uključujući dijabetičku nefropatiju i oksidativni stres. Ovi nalazi pokazuju potencijal mio-inozitola kao dodatne terapije u lečenju dijabetesa i poremećaja lipida. Međutim, potrebna su dalja klinička istraživanja sa većim brojem ispitanika kako bi se u potpunosti razumeli dugoročni efekti i bezbednost kod pacijenata koji boluju od dijabetesa. Ovaj pregled naglašava potrebu za daljim istraživanjima radi optimizacije terapijskih primena mio-inozitola u metaboličkim poremećajima.

Reference

Michell RH. Inositol derivatives: Evolution and functions. Nat Rev Mol Cell Biol. 2008;9(2):151–161. doi: 10.1038/nrm2336.

Chauhan N, Jogpal V. Investigating the role of inositol: Myo-inositol and D-chiroinositol in diabetes: A review. Agri Articles. 2021;10.18805/ag.R-2706.

Caputo M, Bona E, Leone I, et al. Inositols and metabolic disorders: From farm to bedside. J Tradit Complement Med. 2020;10(3):252-259.

Bizzarri M, Carlomagno G. Inositol: History of an effective therapy for Polycystic Ovary Syndrome. Eur Rev Med Pharmacol Sci. 2014;18(13):1896–1903.

Zarezadeh M, Dehghani A, Faghfouri AH, Radkhah N, Kermanshahi MN, Kalajahi FH, Mohammadzadeh Honarvar N, Ghoreishi Z, Ostadrahimi A, Ebrahimi Mamaghani M. Inositol supplementation and body mass index: A systematic review and meta-analysis of randomized clinical trials. Obes Sci Pract. 2021;7(5):569-579. doi: 10.1002/osp4.56.

DiNicolantonio JJ, O'Keefe J. Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. 2022;9:e001989. doi: 10.1136/openhrt-2022-001989.

Condorelli RA, Calogero AE, La Vignera S. Myo-inositol: Does it improve sperm mitochondrial function and sperm motility? Urologia. 2012;79(Suppl 19):24–6. doi: 10.5301/UROLIA.2012.10414.

Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811–1827. doi: 10.1016/j.biochi.2013.05.009.

Maurizi AR, Suraci C, D'Onofrio L, Casagrande V, Barchetta I, Cavallo MG, et al. A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetol. 2017;54(4):361-365. doi: 10.1007/s00592-016-0954-x.

Stanković V, Jović D, Mitić S, Mitić S. Myo-Inositol in Type 1 Diabetes - Case Report. In: Book of Abstracts, 15th International Congress on Nutrition: Food, Nutrition, and Health within the Framework of Sustainable Development; 2024 Nov 20-22; Belgrade, Serbia. Serbian Nutrition Society; 2024. p. 120.

Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997;7(2):147–55. doi: 10.1016/S0924-977X(96)00029-9.

Carlomagno G, Unfer V. Inositol safety: Clinical evidences. Eur Rev Med Pharmacol Sci. 2011;15(8):931–36.

Baldassarre MPA, Di Tomo P, Centorame G, Pandolfi A, Di Pietro N, Consoli A, Formoso G. Myo-inositol reduces inflammation and oxidative stress in human endothelial cells exposed in vivo to chronic hyperglycemia. Nutrients. 2021;13(7):2210. doi: 10.3390/nu13072210.

Bevilacqua A, Bizzarri M. Inositols in insulin signaling and glucose metabolism. Internet J Endocrinol. 2018;2018:1968450.

Chukwuma CI, Ibrahim MA, Islam MS. Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: A dual approach study. J Physiol Biochem. 2016;72:791–801.

Bizzarri M, Fuso A, Dinicola S, Cucina A, Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metabol Toxicol. 2016;12(10):1181-1196.

Matarrelli B, Vitacolonna E, D'Angelo M, et al. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: A randomized controlled trial. J Matern Fetal Neonatal Med. 2013;26:967–72.

Santamaria A, Alibrandi A, Di Benedetto A, et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: A secondary analysis from 3 RCTs. Am J Obstet Gynecol. 2018;219(3):300.e1-e300.e6.

Giordano D, Corrado F, Santamaria A, et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: A perspective, randomized, placebo-controlled study. Menopause. 2011;18:102–4.

Miñambres I, Cuixart G, Gonçalves A, Corcoy R. Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2019;38(3):1146-1152.

Tabrizi R, Ostadmohammadi V, Lankarani KB, et al. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018;17:123.

Fatima K, Jamil Z, Faheem S, Adnan A, Javaid SS, Naeem H, Mohiuddin N, Sajid A, Ochani S. Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: A meta-analysis. Ir J Med Sci. 2023;192(6):2801-2808. doi: 10.1007/s11845-023-03388-5.

Shokrpour M, Foroozanfard F, Ebrahimi F, et al. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: A randomized controlled clinical trial. Gynecol Endocrinol. 2019;35:406–411.

Genazzani AD, Prati A, Simoncini T, Napolitano A. Modulatory role of D-chiroinositol and alpha lipoic acid combination on hormonal and metabolic parameters of overweight/obese PCOS patients. Eur Gynecol Obstet. 2019;1(1):29-33.

Tabrizi R, Ostadmohammadi V, Lankarani KB, et al. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018;17:123.